Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0019682,
umls-concept:C0019691,
umls-concept:C0019699,
umls-concept:C0026473,
umls-concept:C0033684,
umls-concept:C0035820,
umls-concept:C0036667,
umls-concept:C0229671,
umls-concept:C0237401,
umls-concept:C0312418,
umls-concept:C0332307,
umls-concept:C0333516,
umls-concept:C0442805,
umls-concept:C0600531,
umls-concept:C1516743
|
pubmed:dateCreated |
1993-8-25
|
pubmed:abstractText |
Sera of 40 intravenous drug addicts [25 seropositive and 15 seronegative for human immunodeficiency virus (HIV)] were tested for the presence of cytotoxic antibodies against uninfected and HIV-infected monocytic U937 cells. Six of the 25 seropositive samples proved to be cytotoxic for HIV-infected target cells in the presence of complement. The pretreatment of HIV-infected U937 cells with tumour necrosis factor (TNF)-alpha (which enhances virus production in these cells) increased the detection of serum cytotoxicity and 60% of these sera became cytotoxic. The percentage lysis was also increased after the TNF-alpha treatment of the target cells (from 16.2 +/- 4.5 to 71.2 +/- 4.9). The complement-dependent cytotoxic activity of these sera was significantly reduced by pretreatment with recombinant HIV gp120 antigen. This reduction was dose-dependent in the majority of cases. Immunofluorescence studies suggested that the cytotoxic sera mainly interacted with the viral antigens localized on the membrane of HIV-infected TNF-treated U937 cells. Moreover, comparative Western blot analyses using cellular extracts from untreated and TNF-treated U937 cells showed that there was a positive correlation between the cytotoxic phenotype and the capacity of sera to recognize the gp120 protein in extracts from TNF-treated HIV-infected cells. These results suggest that in some circumstances endogenous TNF-alpha can be a protective factor because it can render persistently infected cells highly sensitive to complement-dependent serum cytotoxicity as a result of increased expression of the relevant viral antigen (gp120) on the cell membrane.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Complement System Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Envelope Protein gp120,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0022-1317
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
74 ( Pt 7)
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1271-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8336118-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:8336118-Complement System Proteins,
pubmed-meshheading:8336118-Cytotoxicity, Immunologic,
pubmed-meshheading:8336118-HIV,
pubmed-meshheading:8336118-HIV Envelope Protein gp120,
pubmed-meshheading:8336118-HIV-1,
pubmed-meshheading:8336118-Humans,
pubmed-meshheading:8336118-Monocytes,
pubmed-meshheading:8336118-Recombinant Proteins,
pubmed-meshheading:8336118-Reference Values,
pubmed-meshheading:8336118-Substance-Related Disorders,
pubmed-meshheading:8336118-Tumor Cells, Cultured,
pubmed-meshheading:8336118-Tumor Necrosis Factor-alpha
|
pubmed:year |
1993
|
pubmed:articleTitle |
Tumour necrosis factor-alpha increases the sensitivity of human immunodeficiency virus (HIV)-infected monocytic U937 cells to the complement-dependent cytotoxicity of sera from HIV type 1-infected individuals; role of the gp120 protein.
|
pubmed:affiliation |
Department of Virology, Istituto Superiore di Sanità, Rome, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|